Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

• DOI: 10.1007/s12094-019-02218-4
• Publication Date: 2019-10-30T15:16:46Z
• Authors: P. Garrido; E. Conde; J. de Castro; J. J. Gómez-Román; E. Felip; L. Pijuan; D. Isla; J. Sanz; L. Paz-Ares; F. López-Ríos
• Keywords: Precision oncology

Abstract In 2011 the Spanish Society of Medical Oncology (SEOM) and Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in patients with advanced non-small-cell lung cancer (NSCLC) based current evidence. As this field is constantly evolving, these have been updated, previously 2012 2015 now 2019. Current evidence suggests that mandatory tests conduct all NSCLC are for EGFR BRAF mutations, ALK ROS1 rearrangements PD-L1 expression. The growing need study other emerging biomarkers has promoted routine use massive sequencing (next-generation sequencing, NGS). coordination every professional involved prioritisation most suitable technologies each case remains challenge.